Home/Pipeline/Amportac Platform

Amportac Platform

Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's, ALS)

Pre-clinicalActive

Key Facts

Indication
Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's, ALS)
Phase
Pre-clinical
Status
Active
Company

About Amporin Pharmaceuticals

Amporin Pharmaceuticals is an emerging, private biotech company pioneering a membrane-protecting therapeutic strategy for neurodegenerative and other protein misfolding diseases. Departing from the failed industry focus on insoluble amyloid fibers, Amporin targets the soluble oligomeric pores that disrupt cell membranes and cause degeneration. The company is in the pre-clinical stage, developing three novel, orally available drug classes (Amporbans, Amporins, Amportacs) with a leadership team boasting extensive experience in pharma R&D and neuroscience. Its success hinges on validating a new disease mechanism and translating it into effective, disease-modifying treatments for a large, underserved patient population.

View full company profile

Other Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's, ALS) Drugs

DrugCompanyPhase
Amporban PlatformAmporin PharmaceuticalsPre-clinical
Amporin PlatformAmporin PharmaceuticalsPre-clinical